Association of Male Hypogonadism With Risk of Hospitalization for COVID-19 (2 Sept 2022)

[tareload]

My only issue was the suggestion that there was no clinical data collected in humans, and that the FDA was moving ahead only with data collected it mice. The human data, as limited as it is, has been publicly available since June.

First paragraph I quoted from US today article:


The company has tested the BA.5-specific vaccine only on mice, so far, and is relying on data from both the BA.1 human trials and the BA.5 mice trials for their submission for authorization.



There is no human data for the BA.5 booster.

See the presentation you linked to. At this point why would any company need to use EUA to approve a booster?

Here let me help:

The companies say clinical trials for the BA.4/BA.5 vaccines will begin next month; they need clinical data both for full approval of the vaccines—their recent submissions are only for emergency use authorization—and to help develop future updates. Presumably they will measure recipients’ antibody levels, but not the vaccine’s efficacy against infection or severe disease. Such trials are very expensive and were not done for the BA.1 shot either.

 

[tareload]

COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities

Students at North American universities risk disenrollment due to third dose COVID-19 vaccine mandates. We present a risk-benefit assessment of boosters in this

papers.ssrn.com

Abstract​

Students at North American universities risk disenrollment due to third dose COVID-19 vaccine mandates. We present a risk-benefit assessment of boosters in this age group and provide five ethical arguments against mandates. We estimate that 22,000 - 30,000 previously uninfected adults aged 18-29 must be boosted with an mRNA vaccine to prevent one COVID-19 hospitalisation. Using CDC and sponsor-reported adverse event data, we find that booster mandates may cause a net expected harm: per COVID-19 hospitalisation prevented in previously uninfected young adults, we anticipate 18 to 98 serious adverse events, including 1.7 to 3.0 booster-associated myocarditis cases in males, and 1,373 to 3,234 cases of grade ≥3 reactogenicity which interferes with daily activities. Given the high prevalence of post-infection immunity, this risk-benefit profile is even less favourable. University booster mandates are unethical because: 1) no formal risk-benefit assessment exists for this age group; 2) vaccine mandates may result in a net expected harm to individual young people; 3) mandates are not proportionate: expected harms are not outweighed by public health benefits given the modest and transient effectiveness of vaccines against transmission; 4) US mandates violate the reciprocity principle because rare serious vaccine-related harms will not be reliably compensated due to gaps in current vaccine injury schemes; and 5) mandates create wider social harms. We consider counter-arguments such as a desire for socialisation and safety and show that such arguments lack scientific and/or ethical support. Finally, we discuss the relevance of our analysis for current 2-dose CCOVIDovid-19 vaccine mandates in North America.

 

[BigTex]

Here is the ongoing clinical trial data for the covid vaccines done with humans. The sad thing it is a volunteer reporting system which is estimated to account for only 1% of those receiving the vax.

https://openvaers.com/

 

[tareload]

Whoops...

https://edition.cnn.com/2023/01/11/health/moderna-bivalent-transparency/index.html

$$$

https://genius.com/Ac-dc-moneytalks-lyrics

Of course I gotta post this too, any chance I get:

 

[tareload]

https://www.nejm.org/doi/full/10.1056/NEJMp2215780

 

[BigTex]

How about this one @readalot kind of th elephant in the room so to speak.

Thromboembolic and Thrombocytopenic Events After 3 COVID-19 Vaccines in 3 Nordic Countries

This study evaluates the association between the AZD1222, BNT162b2, and mRNA-1273 vaccines and subsequent thromboembolic and thrombocytopenic events between 3 Nordic countries.

jamanetwork.com

 

[tareload]

COVID-19 Vaccination

COVID-19 vaccines protect against COVID-19. Get safety info and more.

www.cdc.gov

Whatcha talking about BigTex? Nothing to see here, move along

 

[BigTex]

And the CDC keep pumping out those vacccines.

 

[Charliebizz]

And the CDC keep pumping out those vacccines.

And people are still taking them!!!

 

[NeverSayNeverAgain]

And people are still taking them!!!

Are they?

I just checked state by state data on boosters and they are way down from from initial vaccines, I'd say about 15-20% compared to initial double vaccine where the stats are usually 75-95%.

 

[BigTex]

Hey, everytime I turn on the TV they are pumping those vaccine commercials. I am sure the amount of people getting anything past the 1st or 2nd vaccine is dropping quickly.

 

[Charliebizz]

Are they?

I just checked state by state data on boosters and they are way down from from initial vaccines, I'd say about 15-20% compared to initial double vaccine where the stats are usually 75-95%.

it’s still Wild to me. I know so many people who are younger that have gotten 1-2 “boosters” despite them keep catching Covid !! They are convinced it’s why they didn’t “die” or get super sick. Even seeing people who aren’t vaccinated not getting that sick or dying either lol.

 

[BigTex]

Here is another good paper

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potentia…

www.sciencedirect.com

 

[tareload]

Lemme know if anyone wants to see a pretty meticulous tracking of SARS-CoV-2 Antibody Titers before and after COVID infection (documented positive with multiple PCR tests).

164090: SARS-CoV-2 Semi-Quantitative Total Antibody, Spike | Labcorp

Labcorp test details for SARS-CoV-2 Semi-Quantitative Total Antibody, Spike

www.labcorp.com

Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay

Background The Elecsys® Anti-SARS-CoV-2 S immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) has been developed for the in vitro quantitative detection of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein. We evaluated the...

www.medrxiv.org

Ole immune system working pretty decently. I thought antibodies would drop over time as per paper above but haven't found that to be the case (dilutions I think are the same across all data points). Perhaps I have gotten COVID multiple times. First infection was a doozy and subsequent flu like illnesses were not as bad. No positive tests on subsequent illnesses.

[Click to zoom]